探戈治疗
TNGX
22.04
-0.66
-2.91%
探戈治疗
US · TNGX
#2322 按市值排名
上市于 1970
22.04
-0.66
-2.91%
实时 - 追踪5344个代码 - 心跳于403秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 127.87% -0.08pp
- 机构数量
- 292 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund51.47%
Mutual Fund48.92%
VC/PE Fund18.49%
Public Company7.97%
Individual/Insider1.07%
Private Company0.56%
Government Pension Fund0.23%
Insurance Company0.19%
主要股东 截至 2026-06-30
RTW Investments, LP
8.24% · 13.90M 股
BlackRock
7.38% · 12.44M 股
FMR
7.31% · 12.33M 股
Farallon Capital Management, L.L.C.
7.28% · 12.28M 股
Boxer Capital Management, LLC
6.45% · 10.88M 股
The Goldman Sachs Group, Inc.
5.72% · 9.65M 股
TCG Crossover Management, LLC
5.39% · 9.08M 股
Vanguard Capital Management, LLC
4.08% · 6.87M 股
T. Rowe Price Group, Inc.
3.91% · 6.60M 股
Third Rock Ventures, LLC
3.90% · 6.57M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 25次买入 · 22次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Barbara Weber | Chief Executive Officer | 0.92% |
| Daniella Beckman | Chief Financial Officer | 0.08% |
| Mace Rothenberg | Independent Director | 0.02% |
| John Ketchum | Independent Director | 0.01% |
| Adam Crystal | President of Research & Development | 0.01% |
| Jessica Newcomb | -- | 0.01% |
| Lesley Calhoun | Independent Director | 0.01% |
| Malte Peters | Independent Director | 0.01% |
| Alexis Borisy | Independent Chairperson | 0.01% |
| Third Rock Ventures, LLC | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-21 | Jessica Newcomb | -- | Automatic Disposition | -8,200 | $22.80–25.17 |
| 2026-08-31 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–22.37 |
| 2026-08-02 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–27.35 |
| 2026-06-30 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–30.25 |
| 2026-06-18 | Robert Azelby | Independent Director | Other Acquisition | +5,740 | -- |
| 2026-06-18 | Robert Azelby | Independent Director | Other Derivative Acquisition | +35,910 | $27.97 |
| 2026-06-16 | Nextech Invest Ltd. | -- | Intent to Sell (Form 144) | -3,766,081 | $30.10 |
| 2026-06-10 | Daniella Beckman | Chief Financial Officer | Intent to Sell (Form 144) | -1,791,726 | $28.76 |
| 2026-06-09 | Daniella Beckman | Chief Financial Officer | Intent to Sell (Form 144) | -4,446 | $30.00 |
| 2026-06-04 | Mace Rothenberg | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | Mace Rothenberg | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | Lesley Calhoun | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | Lesley Calhoun | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | John Ketchum | Independent Director | Other Acquisition | +4,000 | -- |
| 2026-06-04 | John Ketchum | Independent Director | Other Derivative Acquisition | +25,000 | $20.22 |
| 2026-06-04 | Sung Lee | Director | Other Acquisition | +570 | -- |
| 2026-06-04 | Sung Lee | Director | Other Derivative Acquisition | +3,570 | $20.22 |
| 2026-05-31 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–23.06 |
| 2026-04-30 | Adam Crystal | President of Research & Development | Derivative Exercise and Sale | -27,000 | $5.20–22.00 |
| 2026-04-30 | Matthew Gall | Chief Financial Officer | Other Acquisition | +40,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
探戈治疗 讨论区 0 条评论